IRCT20221227056950N1
Recruiting
Phase 2
The effect of Empagliflozin on left ventricular ejection fraction in non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCI
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Acute anterior ST elevation Myocardial infarction treated with primary PCI.
- Sponsor
- Mashhad University of Medical Sciences
- Enrollment
- 64
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Non\-Diabetic patients
- •Patients with ejection fraction\=40
- •Patients with anterior ST elevation myocardial infarction
- •Patients undergoing primary percutaneous coronary intervention(PCI)
- •The possibility of patient follow up for electrocardiography
- •Consent to admission to the study
Exclusion Criteria
- •Patients who are candidates for medical therapy after angiography
- •Patients who are candidates for CABG after angiography
- •patients with a history of clinical heart failure
- •patients with a history of Anterior STEMI
- •Patients with a history of PCI on LAD
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
The Impact of Empagliflozin on Left Ventricular Myocardial Stiffness in Heart Failure with Preserved Ejection FractioPatients with heart failure with preserved ejecion fraction (HFpEF)Drug intervention, Empagliflozin, Pressure-Volume LoopHFpEF/I509JPRN-jRCTs071230020Hieda Michinari38
Active, not recruiting
Phase 1
Impact of empagliflozin on left ventricular functionstype 2 diabetesMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-002225-10-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA75
Not yet recruiting
Phase 3
Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fractioHeart failure.Heart failure, unspecifiedI50.9IRCT20211219053450N1Ahvaz University of Medical Sciences112
Recruiting
Phase 4
Randomised trial of Empagliflozin and Left ventricular diastolic function in Acute Coronary Syndrome and Type 2 Diabetes (RELACS-T2D)ACTRN12621000355875Fiona Stanley Hospital80
Not yet recruiting
Phase 3
Effect of Empagliflozin on clinical and echocardiographic parameters in patient with reduced LVEF heart failureIRCT20210809052117N1Shahid Beheshti University of Medical Sciences44